Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
ABL Bio
CompanyAlso known as: ABL Bio
Company Profile
ABL Bio is a South Korean biotechnology company focused on bispecific antibody therapeutics across immuno-oncology and neurodegenerative indications. It was founded in 2016 and is headquartered in Seoul. The company is listed on KOSDAQ under ticker 298380.
- Website
- https://www.ablbio.com
- Headquarters
- Seoul, Republic of Korea
- Founded
- 2016
- Stock Ticker
- KOSDAQ:298380
Related News
NEOK Bio Doses First Patients in Phase 1 Trials of Bispecific ADCs NEOK001 and NEOK002
NEOK Bio dosed first patients in Phase 1 trials of lead bispecific ADCs NEOK001 and NEOK002 for advanced solid tumors. The candidates target B7-H3/ROR1 and EGFR/MUC1, with initial data expected in 2027.
ABL111 gains FDA accelerated approval pathway as phase 2 gastric cancer trial begins
ABL111 received FDA agreement on an accelerated approval pathway for metastatic gastric cancer as the first patient was dosed in a global phase 2 trial. The companies said ORR will support accelerated approval and phase 2 is evaluating ABL111 with nivolumab and mFOLFOX6.
Korean Biotechs to Present Next-Gen Cancer Therapies at AACR Meeting
Korean biotech firms will present next-generation cancer therapies at the AACR meeting, including CAR-T platforms for solid tumors, mRNA-based treatments, radiopharmaceuticals, and bispecific antibody ADCs. Companies like AbClon, Verismo Therapeutics, Hanmi Pharmaceutical, and SK Biopharmaceuticals will showcase their latest research.
NovaBridge Enrolls First Patient in Phase 2 Study of Givastomig for Gastric Cancer
NovaBridge Biosciences has enrolled the first patient in a global Phase 2 study evaluating givastomig in combination with nivolumab and chemotherapy for HER2-negative, first-line metastatic gastric cancer, with top-line results expected in 2027.